Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
It could be that Haelix’s dna marker is not altered.
Just a simple piece of strand dna and not modified.
That may be acceptable to organic growers.
But extremely easy to copy. Therefore, useless.
Thx. That white paper is somewhat encouraging.
The Sabby transaction is a new purchase.
After their lprevious filing, they only had a small amount of pre split shares.
Their old warrants are toast.
Yes, and according to Benzinga , the Sabby shares are a new acquisition.
Let the games begin.
Apparently Sabby has taken a 7.16% stake in APDN.
It appears the S-1 delisted the old warrants.
No bid, no ask , no volume on APDNW.
The thing no one is talking about is the volume. Today over 750,000 shares traded.
I calculate that pre 40:1 split that would have been a 14 million share volume.
How does 25% of a company stock trade on a day with no news??
And today was slower than the last 3 sessions.
What is going on??
You have to look at this volume also.
750,000 shares traded today is 1/4 of all the stock, and 1/2 of the stock not held by insiders.
Frankly, I find it very unbelievable.
It looks like it’ll go below 2 this week at the current rate of decline.
That’s not a bad price since they just raised 12 million or $4 book value
It looks like it’ll go below 2 this week at the current rate of decline.
That’s not a bad price since they just raised 12 million or $4 book value
Sabby will be back in for the kill under a buck.
This 12 million won’t last long . Hayward with cash is like a drunk sailor on shore leave.
I was off a little bit: per MarketChameleon:
Applied DNA Sciences Announces Closing of Upsized $12.0 Million Underwritten Public Offering
Business Wire 15-Nov-2019 12:08 PM
Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company") a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing for product authenticity, traceability solutions and nucleic acid-based biotherapeutic research, today announced the closing of its previously announced underwritten public offering of 2,285,000 shares of common stock and warrants to purchase up to an aggregate of 2,285,000 shares of common stock. Each share of common stock was sold together with one warrant to purchase one share of common stock at a combined effective price to the public of $5.25 per share and accompanying warrant. Gross proceeds, before underwriting discounts and commissions and estimated offering expenses, were approximately $12.0 million, not including any amounts received upon exercise of the warrants.
The warrants are immediately exercisable at a price of $5.25 per share of common stock and will expire five years from the date of issuance. The shares of common stock and the accompanying warrants were sold together in the offering, but were issued separately.
Maxim Group LLC acted as the book-running manager and Joseph Gunnar & Co. LLC acted as a co-manager in connection with the offering.
Applied DNA has granted the underwriters a 45-day option to purchase up to an additional 342,750 shares of common stock and/or warrants to purchase up to 342,750 shares of common stock, at the public offering price less discounts and commissions.
The offering was conducted pursuant to the Company's registration statement on Form S-1 (File No. 333-233830), as amended, previously filed with and subsequently declared effective by the Securities and Exchange Commission ("SEC") on November 13, 2019 as well as the Company's subsequent registration statement on Form S-1 (File No. 333-234664), which became effective on November 13, 2019. A final prospectus relating to the offering has been filed with the SEC and is available on the SEC's website at http://www.sec.gov. Electronic copies of the final prospectus relating to this offering may be obtained from Maxim Group LLC, 405 Lexington Avenue, 2nd Floor, New York, NY 10174, at (212) 895-3745.
Shark, if 210,001 shares equals only 6.05%, I calculate:
Approximately 3,490,000 shares outstanding. So, 2,240,000 new shares. So this is a triple dilution.
This means to 1,250,000 shares after the 40/1 split are worth about 1/3 of $6 or $2.
I think we may actually go below that $2.
The old adage: numbers don’t lie.
The resent Maxim buyers have been scammed. This just keeps repeating. They have now lost 1/3 of their investment in 3 days!!
If that wasn’t remarkable enough, the shares of the bag holders are now worth 10 cents.
$4 divided by 40/1 split = 10 cents
NUMBERS don’t lie.
Well, if a leather test took it to 19, maybe a major pharma development would take it to 400.
This is all stranger than I could have dreamt up.
So, Maxim sold 2,250,000 new shares @5.51 raising over 12 million dollars.
There should be about 3.5 million shares issued now.
It looks like Empery Asset Mgmt took a 7.7% stake. So insiders and institutions are nearing 60% ownership.
So, that looks like the retail float is 900,000 shares. This makes any day with trading over 300,000 look fraudulent.
How about a day where 15 million shares traded. ?? How many deficit ave shares are there??
It appears that the 40:1 reverse split didn’t reverse split everyone’s shares or options.
That would explain the one day run up and next day dump which saw approximately 20 million shares traded.
How do you do that with 1,250,000 shares outstanding
As we have seen year after year, that never works.
Go to Vegas, put your proposed investment on Red.
You get a 50/50 chance.
You won’t get those odds here
I think what we see unfolding is a catch 22.
He needed to get the stock price up thus the 40:1 reverse split.
Now Maxim is trying to raise 8million on new stock offering which will at this pps dilute the stock by another 300-400%.
All to stay listed? Unfortunately for us, we have never been given a reason or guidance for all this.
If the reverse split was done to enable dumping new stock on the market, then on defeats the other.
Everybody, except Hayward loses. Hayward gets paid another year to man a ship that has sunk.
I think it will drop back below 1.
Hayward/Maxim are trying to raise 8 million.
They are calling and phoning shareholders to buy more.
A restructuring specialist is most effective at improving margins at companies with sales but poor bottom line.
I have noticed an inordinate amount of money being spent on trade shows and testing programs / LOI.
Also, based on sales , I doubt 50+ employees are needed.
I think a lot of them are getting coffee for Hayward and telling him how wonderful he is.
Kind of like Trump’s Cabinet.
There is something wrong with the efficacy of the marking system. This was brought up at the last conference call and it relates directly to failed testing with Colorcon pharma customers.
No updates on this.
According to last quarter’s CC, there was a problem uncovered during pilot tests with Colorcon.
I am assuming this “problem “ has affected cotton, pharma etc,etc.
It sounded like a long term efficacy with the dna marker. Haywardalluded to this several times and said it was being quickly resolved.
Who knows??
Well, whatever the case is or seems to be, one thing is proven in numbers.
We’re down another 30-40% since the stock split.
It looks like dumping by the company to raise funds. Maxim is handling some sort of stock sale and calling shareholders to buy more stock.
Hayward is trying to raise 8 million$$. So at today’s price it would be about another 60-70 % dilution.
We may go back below a buck at this rate
I really think trutag is in the packaging. Apdn marks the plat. Jmho
The only problem with that response:
Dark Periods do not exempt public corporations from their timely requirements to announce any material event.
You can deduct from that , APDN is a “component “ of Etch Biotrace, and there is no change.
If they had ended the contract with Theracan, it would most certainly be a material event and a 4 million hit to revenue.
So the shareholders pre 2014 now have 1 share for every 2000 original shares.
Is this Argentina??
On the vote. Is it no on 1, yes on 2??
Let me know shark
i believe it was millions of sharest 55cents
All this tells us one thing. And it’s dismal.
Hayward, by pushing the reverse split has stated loud and clear that there will be no developments between now and December 31 to move this stock upward.
And that means after the split, things get worse.
Been down this road a few times Shark.
They get another hearing at the end of December, then another 90 day extension. As long as they show some progress in the plan they submitted, this can go on indefinitely.
This company is remarkable in its inability to secure meaningful business over a period of decades now.
There was some problem with the marking that Hayward stated in the last conference call. He said they were working with Colorcon and some pharmaceuticals to resolve this.
We were told last February that a Colorcon contract was coming, then once again Colorcon and Videojet contracts by last September. Nothing happened .
No updates on what the “problem “ is.
Really, this has all gone on too long.
Even if a reverse split gets the price up to 4 bucks and they get the 2.5 million in equity....
It will only take another poor quarter to sink right back down.
Investors need a reason from Hayward that makes sense.
No more gobbledy gook
Even more dismal. Hayward knows nothing happening between now and 12/31/19 will improve share price.
Only a desperate reverse split.
That means 4th Q was a dud and this quarter will be worse.
There is literally nothing happening in the future performance to give any help/hope.
So, the conversion of the debt increased stockholders equity and reverse split for the share price.
The pieces fall into place.
Once again, performance is meaningless.
I’m opposed simply because enough is enough. When Hayward’s little personal company shows some contracts and shows a profit the share price will go up
Then they can get back in Nasdaq. The OTC is fine with me.
The only reason for staying on Nasdaq is to sell more shares.
Consistently Hayward has been doing shelf offerings over the last five years to garner cash flow.
Why? Because it’s the only source of cash flow. Hayward and the board of directors have never been able to generate cash flow through operations.
Further insult...non performing employees and board members are consistently paid with stock, further diluting retail investors.
I’ve been watching this broken record for a long time. NASDAQ is plainly and simply Hayward’s cash cow. All the while having shills on this board pumping “ just wait for 2 years”, over the last 29 years.
I does seem certain that any positive news in the next 180 days would preempt the need for a reverse split.
To me, that means the contracts with Colorcon and Videojet never existed. Not even the hope for one.
You’re right . Hayward treats this company as being his private possession.
After many positive comments about the coming contracts, there is never an explanation as to why they never materialized.